Dynepo is a form of pharmaceutical erythropoietin (EPO) under development as a pharmaceutical product by Shire Pharmaceuticals. The first development steps were performed by HMR and Aventis. Aventis obtained the license in Europe in 2002. The company expects to launch the product in Europe in 2006, although patents held by the American biotechnology company Amgen, Inc. may preclude its sale in the United States.
EPO is a natural human hormone that stimulates formation of red blood cells. Pharmaceutical EPO, made via recombinant DNA technology is used to treat anemia, but it has also been used by doping athletes to improve their aerobic performance and stamina.
Unlike existing forms of pharmaceutical EPO manufactured in cultured animal cells, Dynepo is to be made in cultured human cells. It is therefore expected to have an authentic human form of sialic acid and other oligosaccharide residues. This characteristic may make it a longer-acting product than existing brands, but clinical data have not yet been made public. It should also make Dynepo undetectable in the existing urine test for EPO used to detect doping by athletes. However, on September 28, 2007, the French sports newspaper L'Equipe reported that the French anti-doping laboratory LNDD had detected Dynepo in the urine of Michael Rasmussen during the 2007 Tour de France. Rasmussen was sacked by his own team while leading the Tour, because of irregularities in his reporting of his whereabouts during the lead-up to the tour. The story also remarked that Dynepo was found in the urine of several other riders, yet criteria for a positive test for Dynepo are not defined.
On July 1, 2009, professional cycling team Template:Ct announced that Thomas Dekker was tested positive for dynepo on a test taken on December 24, 2007, while Dekker was riding for Template:Ct.
Dynepo Pharmaceutical References
Dynepo EPAR (European Public Assessment Report), PDF format , credit European Medicines Agency
"This document is a summary of the European Public Assessment Report (EPAR). It explains how the Committee for Medicinal products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine. If you need more information about your medical condition or your treatment, read the Package Leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the Scientific Discussion (also part of the EPAR).
...This summary was last updated in 03-2007."
|This pharmacology-related article is a stub. You can help Wikipedia by expanding it.|